Phase separation underlies signaling activation of oncogenic NTRK fusions

Pharmacological inhibition of SRC-1 phase separation suppresses YAP oncogenic transcription activity

Phase Separation of Disease-AssociatedSHP2 Mutants Underlies MAPK Hyperactivation

Inhibition of cIAP1 as a strategy for targeting c-MYC–driven oncogenic activity

Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment

c-IAP1 Cooperates with Myc by Acting as a Ubiquitin Ligase for Mad1